NCT07780539Not yet recruiting
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2028
- Lead sponsor
- Yefeng
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT07780539
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Sept 2026 to the primary completion date, 1 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
Other illness
- History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
- Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
- Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
- Any condition deemed by the investigator as unsuitable for study drug treatment.
Who the study is looking for
- Patients with pathologically or cytologically confirmed neuroendocrine tumors;
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
- Life expectancy ≥ 12 weeks;
- Adequate organ and bone marrow function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated hospital of Xiamen University Coordinator of this site? Confirm its status | Xiamen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.